Inclusion Criteria:

          -  Individuals able to understand and give written informed consent.

          -  Histologically or cytologically confirmed epithelial cancer of one of the following
             types:

               -  Gastric adenocarcinoma (GC)

               -  Esophageal cancer (EC)

               -  Hepatocellular carcinoma (HCC)

               -  Non-small-cell lung cancer (NSCLC)

               -  Small-cell lung cancer (SCLC)

               -  Epithelial ovarian cancer (EOC)

               -  Cervical Cancer

               -  Endometrial Cancer

               -  Triple-negative breast cancer (TNBC)

               -  Non-triple-negative breast cancer

               -  Papillary thyroid cancer (excludes follicular, medullary, Hurthle cell, and
                  anaplastic thyroid cancer)

               -  Glioblastoma multiforme (GBM)

               -  Hormone-refractory prostate cancer (HRPC)

               -  Head and neck cancers- squamous cell (SCCHN)

               -  Renal cell cancer (clear cell) (RCC)

               -  Urothelial cancer

               -  Stage IV (metastatic) disease (except for individuals with GBM).

          -  Refractory to or relapsed after at least one prior standard therapeutic regimen

          -  Adequate performance status (ECOG 0 or 1)

          -  Expected survival ≥ 6 months.

          -  Measurable disease by CT or MRI.

          -  At least 2 weeks beyond treatment (chemotherapy, investigational drugs including small
             molecular inhibitors, immunotherapy and/or radiation therapy) or major surgery and
             recovered from all acute toxicities to Grade 1 or less (except alopecia).

          -  At least 2 weeks beyond high dose systemic corticosteroids (however, low dose
             corticosteroids < 20 mg prednisone or equivalent daily are permitted).

          -  Adequate hematology without ongoing transfusional support (hemoglobin > 9 g/dL,
             absolute neutrophil count (ANC) > 1,500 per mm^3, platelets > 100,000 per mm^3).

          -  Adequate renal and hepatic function (creatinine ≤ 2.0 x institutional upper limit of
             normal (IULN), bilirubin ≤ 1.5 IULN, aspartate aminotransferase (AST) and alanine
             aminotransferase (ALT) ≤ 3.0 x IULN or 5 x IULN if know liver metastases).

          -  Otherwise, all toxicity at study entry ≤ Grade 1.

        Exclusion Criteria:

          -  Women who are pregnant or lactating.

          -  Women of childbearing potential and fertile men unwilling to use effective
             contraception during study until conclusion of 12-week post-treatment evaluation
             period.

          -  Individuals with Gilbert's disease.

          -  Individuals with brain metastases can be enrolled only if treated, non-progressive
             brain metastases and off high-dose steroids (> 20 mg prednisone or equivalent) for at
             least 4 weeks.

          -  Presence of bulky disease (defined as any single mass > 7 cm in its greatest
             dimension). Individuals with a mass over 7 cm, but otherwise eligible, may be
             considered for enrollment after discussion and approval with the medical monitor.

          -  Individuals with active ≥ grade 2 anorexia, nausea or vomiting, and/or signs of
             intestinal obstruction.

          -  Individuals with non-melanoma skin cancer or carcinoma in situ of the cervix are
             eligible, while individuals with other prior malignancies must have had at least a
             3-year disease-free interval.

          -  Individuals known to be HIV positive, hepatitis B positive, or hepatitis C positive.

          -  Known history of unstable angina, MI, or CHF present within 6 months or clinically
             significant cardiac arrhythmia (other than stable atrial fibrillation) requiring
             anti-arrhythmia therapy.

          -  Known history of clinically significant active COPD, or other moderate-to-severe
             chronic respiratory illness present within 6 months.

          -  Prior history of clinically significant bleeding, intestinal obstruction, or GI
             perforation within 6 months of initiation of study treatment.

          -  Infection requiring intravenous antibiotic use within 1 week.

          -  History of an anaphylactic reaction to irinotecan or ≥ Grade 3 GI toxicity to prior
             irinotecan,

          -  Other concurrent medical or psychiatric conditions that, in the Investigator's
             opinion, may be likely to confound study interpretation or prevent completion of study
             procedures and follow-up examinations.